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ORIGINAL ARTICLE
Cluster-Randomized Trial of a Behavioral
Intervention to Incorporate a Treat-to-Target
Approach to Care of US Patients With
Rheumatoid Arthritis
LESLIE R. HARROLD,1 GEORGE W. REED,1 ANI JOHN,2 CHRISTINE J. BARR,3 KEVIN SOE,3
ROBERT MAGNER,4 KATHERINE C. SAUNDERS,3 ERIC M. RUDERMAN,5 TMIRAH HASELKORN,2
JEFFREY D. GREENBERG,6 ALLAN GIBOFSKY,7 J. TIMOTHY HARRINGTON,8 AND JOEL M. KREMER9
Objective. To assess the feasibility and efficacy of implementing a treat-to-target approach versus usual care in a
US-based cohort of rheumatoid arthritis patients.
Methods. In this behavioral intervention trial, rheumatology practices were cluster-randomized to provide treat-to-
target care or usual care. Eligible patients with moderate/high disease activity (Clinical Disease Activity Index [CDAI]
score >10) were followed for 12 months. Both treat-to-target and usual care patients were seen every 3 months. Treat-
to-target providers were to have monthly visits with treatment acceleration at a minimum of every 3 months in
patients with CDAI score >10; additional visits and treatment acceleration were at the discretion of usual care pro-
viders and patients. Coprimary end points were feasibility, assessed by rate of treatment acceleration conditional on
CDAI score >10, and achievement of low disease activity (LDA; CDAI score ≤10) by an intent-to-treat analysis.
Results. A total of 14 practice sites per study arm were included (246 patients receiving treat-to-target and 286 receiving
usual care). The groups had similar baseline demographic and clinical characteristics. Rates of treatment acceleration
(treat-to-target 47% versus usual care 50%; odds ratio [OR] 0.92 [95% confidence interval (95% CI) 0.64, 1.34]) and achieve-
ment of LDA (treat-to-target 57% versus usual care 55%; OR 1.05 [95% CI 0.60, 1.84]) were similar between groups. Treat-
to-target providers reported patient reluctance and medication lag time as common barriers to treatment acceleration.
Conclusion. This study is the first to examine the feasibility and efficacy of a treat-to-target approach in typical US
rheumatology practice. Treat-to-target care was not associated with increased likelihood of treatment acceleration or
achievement of LDA, and barriers to treatment acceleration were identified.
INTRODUCTION
The ultimate goal of treatment of rheumatoid arthritis (RA)
is achievement of clinical remission, or at least low disease
activity (LDA) when remission is not possible due to
comorbidities that prohibit treatment intensification or in
cases of established RA (1). There is a growing consensus
that the use of a treat-to-target approach optimizes clinical
outcomes in patients with RA. Treat-to-target care requires
frequent assessment of patient disease activity using
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validated measures and acceleration of treatment until
remission or LDA is achieved (1). Such frequent monitoring
can be used to measure and document treatments and
assess whether a treatment is effective or should be altered
(2).
Multiple studies have suggested an advantage of treat-to-
target management over usual care. The Tight Control of
Rheumatoid Arthritis (TICORA) trial demonstrated that
mandated treat-to-target treatment led to greater reduction
in disease activity and higher remission rates than usual
care (3). The TICORA findings have been supported by sev-
eral other studies, including data from the Dutch Rheuma-
toid Arthritis Monitoring Registry and the Computer
Assisted Management in Early Rheumatoid Arthritis trial,
which demonstrated greater improvement in the 28-joint
Disease Activity Score (DAS28) in patients with early RA
treated with a treat-to-target strategy (4,5). Importantly,
these trials were conducted in Europe, and it is possible
that differences in health care systems, physician practice
structure, and patient characteristics may affect
applicability of these results to US rheumatology. Addition-
ally, these trials were predominantly conducted in patients
with early RA and, in some cases, prior to the use of bio-
logic agents.
The feasibility of a treat-to-target approach for the rou-
tine care of patients in typical clinical practice in the US
has not been evaluated. Specifically, adapting a treat-to-
target approach to RA care for US rheumatologists and
their patients in busy clinical practices needs to be
assessed. Potential barriers to widespread implementation
of a treat-to-target strategy include the increased frequency
of visits mandated by treat-to-target recommendations,
which may be challenging given limited provider avail-
ability (e.g., limited followup appointments) and busy
patient and clinic schedules (6). Routine acceleration of
therapy may be challenging due to patient out-of-pocket
expenses for travel and copays at the time of additional
appointments, denials or delays in medications by insur-
ers, clinical inertia on the part of physicians, and patient
reluctance to increase or change medication frequently.
Considering these potential barriers, evaluating the chal-
lenges and feasibility of treat-to-target implementation in a
US patient population is important. We designed a cluster-
randomized behavioral intervention trial targeting rheuma-
tologists to facilitate the implementation of the treat-to-target
approach for all patients, irrespective of disease duration, in
a variety of US rheumatology practices. The coprimary
objectives were to assess the feasibility of implementing a
treat-to-target approach in US rheumatology practices and to
compare the efficacy of treat-to-target care versus usual care
in achievement of LDA; these were selected as coprimary
objectives because efficacy is likely related to the feasibility
of implementing the treat-to-target approach.
PATIENTS AND METHODS
Study population. The design and rationale for the study
have been reported previously (7). Briefly, rheumatology
practices that were affiliated with the CORRONA RA
registry (comprising >160 private and academic practice
sites across 40 US states) and practices that were not
affiliated were approached regarding participation (8,9).
Eligible sites that agreed to participate were stratified by the
number of patients they anticipated enrolling and cluster-
randomized 1:1 to administer treat-to-target care or usual
care to enrolled patients, with the patient as the unit of
analysis. All patients enrolled at a site received the same
study arm assignment of care. This cluster-randomization
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Significance & Innovations
• This was the first study to examine both feasibil-
ity and efficacy of implementing a treat-to-target
approach to the care of patients with rheumatoid
arthritis in typical clinical practice in the US.
• The frequency of treatment acceleration was simi-
lar between the treat-to-target and usual care
approaches, with acceleration occurring at approx-
imately 47% of visits at which a patient had a
Clinical Disease Activity Index (CDAI) score >10
in either arm; the most frequent reasons for not
accelerating therapy in treat-to-target patients with
CDAI score >10 were patient preference and physi-
cians suspecting a lag in response to medication.
• Treat-to-target and usual care were equally effec-
tive in achievement of low disease activity (LDA)
over time and at the 12-month end point, with
approximately 60% of patients in either arm
achieving LDA at 12 months.
• These results provide important insights into
improving implementation of a treat-to-target
approach in everyday practice, particularly the
need for patient engagement.
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approach was used to address the concern of unintended
crossover, because for rheumatologists to give usual care if
they were also caring for patients randomized to the treat-to-
target arm would be challenging. This approach was also
used to address potential overlapping influence that might
introduce bias if the same staff members at a study site were
assigned to different treatment arms. Based on the power
analyses described previously, our goal was to enroll a total
of 530 patients, with 265 (17–18 patients at each of 15 sites)
randomized per study arm (7). Sample size was determined
based on the primary outcome of achievement of LDA, using
historical CORRONA data that revealed an LDA achieve-
ment rate of 40% using the study inclusion criteria. The
comparison of treat-to-target versus usual care had 80%
power to detect an odds ratio (OR) of ≥1.50, which
represents anticipated LDA rates of 60% in the treat-to-target
arm versus 40% in the usual care arm.
Patients were invited to participate by their practicing
rheumatologist. Eligible patients were outpatients ages
≥18 years who met the 2010 revised American College of
Rheumatology criteria for the diagnosis of RA (10), had
moderate to severe disease activity based on Clinical Dis-
ease Activity Index (CDAI) score >10, and were deemed
medically appropriate for treatment acceleration by their
rheumatologist. Patients were required to agree to the
schedule of study visits (including the possibility of
more frequent visits in the treat-to-target arm), be willing
to have their therapy escalated as appropriate, and pro-
vide informed consent. Patients were included regardless
of RA disease duration or prior medication use to ensure
a typical practice sample of participants. Patients consid-
ered ineligible for treatment acceleration were excluded
from the study (7). Practices were recruited from June
2011 through June 2013, with the first patient visit on
July 29, 2011, and the last on July 29, 2014. The study
was conducted per the current (2013) version of the Dec-
laration of Helsinki. Institutional review board (IRB)
approvals were obtained from local IRBs of participating
academic sites and a central IRB (New England IRB) for
private practice sites, and were required before study
participation and randomization.
Study design. Both treat-to-target and usual care patients
had mandated research visits every 3 months, at which time
they completed CORRONA questionnaires (Figure 1). Clini-
cal data, including CDAI score and medication use, were
collected at each visit. Frequencies of visits, all changes in
medication, and any adverse events (AEs) were tracked
throughout the course of the study.
Intervention. All treat-to-target providers and sites
received a training session on the treat-to-target treatment
paradigm, including measuring disease activity using the
CDAI score at every visit, and were asked to schedule
monthly visits until LDA (CDAI score ≤10) was achieved
according to the 2010 international recommendations (11).
Prompts for treatment acceleration in the setting of elevated
disease activity were provided through study questionnaires
in the treat-to-target arm. Training was supplemented with
informational e-mails, newsletter reminders, site feedback,
and telephone discussions to reinforce the treat-to-target
philosophy. Providers in the treat-to-target arm were to
escalate therapy no less frequently than every 3 months if
LDA had not been achieved, unless good clinical practice
dictated otherwise in the event of a contraindication or
patient unwillingness to change therapy. Reasons for not
accelerating treatment were recorded by the investigators.
Treatment acceleration was defined as a dosage increase, the
addition of or switch to a conventional synthetic disease-
modifying antirheumatic drug (csDMARD) or biologic agent,
or a change from oral to subcutaneous methotrexate.
Initiation or increased dosing of glucocorticoids was not
considered treatment acceleration. Due to the behavioral
intervention design of the trial, providers in the treat-to-
target arm were not audited for adherence to the treat-to-
target approach during the study and received no feedback
Figure 1. Study design. UC = usual care; T2T = treat-to-target; CDAI = Clinical Disease Activity Index score.
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on their performance. In the usual care group, the frequency
of any additional visits and treatment acceleration was left
to the discretion of investigators and patients. Usual care
providers were made aware prior to receiving their
treatment arm assignment that a treat-to-target intervention
would be compared with usual care.
Outcome measures. The predefined coprimary outcomes
were the feasibility of implementing a treat-to-target approach
to care in US rheumatology practice, and the efficacy of treat-
to-target care versus usual care in the achievement of LDA.
Feasibility of the treat-to-target approach was assessed by
comparing the rates of treatment acceleration conditional on
moderate or high disease activity in the 2 groups. Efficacy
was evaluated by the achievement of LDA as defined
by CDAI score ≤10 at 12 months by an intent-to-treat
analysis.
Secondary objectives were to compare between the 2
study arms: the change in CDAI score from baseline to
12 months, the proportion of patients in LDA at each
mandated research visit (3, 6, 9, and 12 months), the
mean CDAI score over time in the total population and
in patients not in LDA overall and those with no treat-
ment accelerations in the prior 3 months, trends in treat-
ment acceleration over time, and the rates of infection,
cardiovascular, and malignancy AEs over the study peri-
od. In the treat-to-target arm, the reasons for lack of
acceleration for all visits with a CDAI score >10 were
evaluated. Subanalyses limiting the sample to those vis-
its without a treatment acceleration in the prior 3 months
were also performed.
Statistical analysis. The characteristics of patients
enrolled into the treat-to-target and usual care arms were
compared using standardized differences, which are less
influenced by sample size. Feasibility of the treat-to-target
approach was assessed by comparing the rate of treatment
acceleration conditional on CDAI score >10 between the
treat-to-target and usual care arms. The rate of achievement
of LDA (CDAI score ≤10) at 12 months was analyzed
using an intent-to-treat approach. In a subanalysis, the rate
of achievement of LDA at 12 months was examined using
only those patients who completed the study. The rates of
acceleration and achievement of LDA were adjusted for
clustering of patients by physician and physicians
by practice sites, as well as baseline covariates with
|standardized differences| >0.1, using linear random-
effects mixed models. A standardized difference <0.1
has been taken to indicate a negligible difference in the
mean or prevalence of a covariate between treatment
groups (12,13). Multiple imputation using chained
equations was performed to replace missing values for
covariates associated with the primary efficacy outcome,
achievement of LDA (14).
Change in CDAI score at 12 months was compared
between groups using linear mixed models and an
intent-to-treat approach adjusting for clustering and
covariates as outlined for the primary outcome. The pro-
portion of patients with LDA in both the treat-to-target
and usual care groups at each research visit (3, 6, 9, and
12 months) was determined in the intent-to-treat popula-
tion. The mean CDAI score for all visits in the total study
population and among patients who did not achieve
Figure 2. Study flow diagram. T2T = treat-to-target; UC = usual care; a = reasons for site exclusion were refusal to participate, inability
to initiate in time to recruit, or lack of response to outreach; b = reasons for patient exclusion were low disease activity (T2T, n = 2;
UC, n = 2) and missing Clinical Disease Activity Index score (UC, n = 1).
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LDA overall and those with no treatment accelerations in
the previous 3 months was examined. The occurrence of
infection, cardiovascular, and malignancy AEs was com-
pared between groups using a time to first event in the
category approach and the log-rank test to evaluate dif-
ferences. The probability of acceleration based on CDAI
score >10 at each visit was calculated by identifying all
visits for each patient at which CDAI score >10 occurred
(all eligible accelerations) and determining how many of
these visits were associated with a treatment acceleration
by the end of the visit or by the next visit. In a subanalysis,
we excluded visits where there had been an acceleration
in the prior 3 months (eligible new accelerations), as
these patients were likely not candidates for acceleration
due to the recent medication change. As supplementary
information, we provided both unadjusted and adjusted
(for clustering and baseline values) changes in World
Health Organization/International League of Associations
of Rheumatology (WHO/ILAR) core set outcomes (tender
and swollen joint counts, pain, physician and patient
global assessments, Health Assessment Questionnaire
score, and erythrocyte sedimentation rate) (15).
RESULTS
Patient demographics and baseline characteristics. A
total of 106 sites were approached. Thirty-one sites agreed
to participate and were able to comply with the study
protocol, 16 of which were randomized to the treat-to-target
arm and 15 to the usual care arm. Two practices in the
treat-to-target group and 1 in the usual care group did not
Table 1. Baseline demographics of the treat-to-target and usual care study populations*
Treat-to-target
(n = 246)
Usual care
(n = 286)
Standardized differencesNo. Value No. Value
Age, years 240 57.0  12.8 271 58.0  13.1 0.08
Female, no. (%) 246 196 (79) 286 224 (79) 0.01
Hispanic, no. (%) 210 47 (22) 219 18 (8) 0.40
Race, no. (%)
White 206 181 (88) 250 224 (90) 0.06
African American 206 15 (7) 250 14 (6) 0.07
Asian 206 3 (2) 250 3 (1) 0.02
Other/mixed 206 7 (3) 250 9 (4) 0.01
College educated, no. (%) 236 133 (56) 277 160 (58) 0.03
Part- or full-time employment, no. (%) 243 119 (49) 280 141 (50) 0.03
Insurance, no. (%)
Private 224 168 (75) 264 202 (77) 0.04
Medicare 224 60 (27) 264 86 (33) 0.13
Medicaid 224 18 (8) 264 12 (5) 0.14
No insurance 224 10 (5) 264 9 (3) 0.05
RA characteristics
Disease duration, years 245 7.3  9.5 282 8.4  9.4 0.12
RF seropositivity, no. (%) 184 124 (67) 207 153 (74) 0.14
HAQ DI (0–3) 234 1.1  0.7 266 1.0  0.7 0.07
Disease activity
CDAI (0–76) 246 26.7  13.4 286 25.5  11.8 0.09
CDAI disease activity category, no. (%)
Moderate (CDAI >10 to ≤22) 246 121 (49) 286 139 (49) 0.01
High (CDAI >22) 246 125 (51) 286 147 (51) 0.01
TJC (0–28) 246 8.0  7.0 286 7.8  5.5 0.03
SJC (0–28) 246 8.1  5.6 286 7.3  5.1 0.14
ESR, mm/hour 211 28.5  24.9 240 29.8  23.8 0.05
CRP, mg/dl 72 32.6  83.7 166 24.6  87.8 0.09
Medication, no. (%)
Biologic agent naive 246 140 (57) 286 158 (55) 0.03
Current glucocorticoid 246 92 (37) 286 103 (36) 0.03
Current biologic agent/small molecule† 246 54 (22) 286 79 (28) 0.13
Current csDMARDs‡ 246 85 (35) 286 120 (42) 0.15
Current MTX 246 165 (67) 286 186 (65) 0.04
* Values are the mean  SD unless indicated otherwise. RA = rheumatoid arthritis; RF = rheumatoid factor; HAQ DI = Health Assessment
Questionnaire Disability Index score; CDAI = Clinical Disease Activity Index score; TJC = tender joint count; SJC = swollen joint count;
ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; csDMARDs = conventional synthetic disease-modifying antirheumatic
drugs; MTX = methotrexate.
† All patients undergoing treatment with a biologic agent or small molecule, with or without concurrent use of csDMARDs, at enrollment.
‡ Patients treated with csDMARDs without a concurrent biologic agent or small molecule at enrollment.
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enroll any patients; 14 study sites per group were included
in the final analysis. The total number of patients eligible
for inclusion in the analysis was 246 (median [range] 12
[5–41] patients per site) in the treat-to-target arm and 286
(median [range] 13.5 [2–40] patients per site) in the usual
care arm. Of the eligible enrolled patients, 197 patients
(80%) in the treat-to-target arm and 239 patients (84%) in
the usual care arm completed the study (Figure 2).
Patient demographics and baseline disease characteris-
tics were mostly similar between intervention groups
(Table 1), except for a larger proportion of self-reported
Hispanic patients in the treat-to-target arm (22%) com-
pared with the usual care arm (8%). In the treat-to-target
arm, mean  SD age was 57  12.8 years, 80% of patients
were women, and mean  SD RA disease duration was 7.3
 9.5 years. In the usual care arm, mean  SD age was 58
 13.1 years, 79% of patients were women, and mean 
SD RA disease duration was 8.4  9.4 years.
Primary outcomes. The frequency of visits was signif-
icantly greater in the treat-to-target arm than the usual care
arm, with a mean number of visits per person-year of
followup of 7.68 and 5.58, respectively (P < 0.001).
However, there was no difference in the overall probability
of treatment accelerations for patients with CDAI score >10
between the treat-to-target and usual care arms (Figure 3A),
with approximately 47% of visits in either arm associated
with therapy escalation.
Similarly, there was no significant difference between the
treat-to-target and usual care groups in the achievement of
LDA (P = 0.665) (Figure 3A). At last followup, 139 patients
(57%) in the treat-to-target group and 156 (55%) in the usual
care group had achieved LDA (CDAI score ≤10). This simi-
larity in efficacy was consistent when rates of LDA were
restricted to only those patients who completed the study
(P = 0.434). Models adjusting for clustering and baseline
characteristics revealed no significant difference
between the treat-to-target and usual care arms for
either the feasibility or efficacy outcomes (Figure 3B).
Secondary outcomes. Secondary analyses comparing
change in CDAI score in the treat-to-target versus usual care
arms, adjusted for clustering and baseline characteristics,
showed no significant difference at 12 months (0.61 [95%
confidence interval 2.02, 3.24]). There were no differences
between the 2 groups in the proportion of patients with
LDA at each visit (see Supplementary Figure 1, available
on the Arthritis Care & Research web site at http://online
library.wiley.com/doi/10.1002/acr.23294/abstract) or in the
mean CDAI score over time in the total population or in
patients eligible for acceleration (CDAI score >10) (see
Supplementary Figure 2, available on the Arthritis Care &
Research web site). There were no differences in the change
in WHO/ILAR core set outcomes (see Supplementary
Table 1, available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23294/
abstract). The rates of serious infections (4.7 per 100 patient-
years versus 4.3 per 100 patient-years), cardiovascular
events (2.3 per 100 patient-years versus 3.1 per 100 patient-
years), and cancers (0.5 per 100 patient-years versus 0.8 per
100 patient-years) were similar in the treat-to-target versus
usual care groups (see Supplementary Table 2, available on
theArthritis Care & Researchweb site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23294/abstract).
Treatment acceleration over time. Over time, there was
a decrease in the rate of accelerations per visit in both
groups. In the treat-to-target arm, the proportion of all
eligible acceleration visits at which treatment acceleration
occurred was 70% at enrollment, 43% at 3 months, 39% at
Figure 3. Outcomes in the treat-to-target (T2T) versus usual care (UC) groups at 12 months. A, Unadjusted response rates at 12 months.
B, Odds ratio (OR) comparing response rates with T2T versus UC at 12 months, adjusted for clustering and patient baseline characteris-
tics. 95% CI = 95% confidence interval; a = the primary feasibility outcome was the probability of treatment acceleration conditional on
Clinical Disease Activity Index score >10; b = the primary efficacy outcome was overall achievement of low disease activity (LDA); c =
the secondary efficacy outcome was achievement of LDA among patients who completed the study (analysis of those who completed);
d = T2T versus UC adjusted for clustering by physician for the efficacy outcomes and for clustering by patient, physician, and practice
site for the feasibility outcomes; e = adjusted for age, Hispanic ethnicity, Medicare insurance, rheumatoid factor seropositivity, disease
duration, number of prior biologic agents, number of prior conventional synthetic disease-modifying antirheumatic drugs, current bio-
logic agent/small molecule use, and clustering.
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6 months, and 29% at 9+ months; in the usual care arm, it
was 60% at enrollment, 41% at 3 months, 39% at 6
months, and 28% at 9+ months (Figure 4A). A similar
decrease in accelerations over time was observed when
visits with treatment acceleration in the prior 3 months
were excluded to account for patients who were less-likely
candidates for acceleration due to a recent medication
change. The proportion of eligible new acceleration visits
at which treatment acceleration occurred in the treat-to-
target arm was 73% at enrollment, 46% at 3 months, 42%
at 6 months, and 31% at 9+months; in the usual care arm it
was 61% at enrollment, 42% at 3 months, 42% at 6
months, and 25% at 9+ months (Figure 4B). There was no
significant difference between the groups in the proportion
of visits with treatment acceleration over time following
enrollment (Figure 4).
The most frequent reason for not accelerating treatment
was physician concern about medication response time
lag (53%), when the provider thought more time was
needed to allow the medication to have maximal effect
Figure 4. Patterns of treatment acceleration over time. A, Proportion of all eligible acceleration visits at which treatment was accelerated.
B, Proportion of eligible new acceleration visits at which treatment was accelerated. T2T = treat-to-target; UC = usual care; 95% CI = 95%
confidence interval; a = total number of patient visits within the indicated time period with Clinical Disease Activity Index score >10
and no accelerations within the previous 3 months.
Table 2. Possible reasons for nonacceleration in patients with Clinical Disease Activity Index (CDAI) score >10 in the
treat-to-target study arm*
Reason†
All visits, month no.‡
Visits without treatment acceleration in
prior 3 months, month no.‡
1–3
(n = 150)
4–6
(n = 98)
7–9
(n = 70)
10–12+
(n = 69)§ Overall
1–3
(n = 48)
4–6
(n = 42)
7–9
(n = 30)
10–12+
(n = 45)§ Overall
Medication response
time lag
68.0 56.1 48.6 21.7 53.2 39.6 38.1 26.7 13.3 29.7
Patient preference 24.7 28.6 38.6 52.2 33.1 50.0 38.1 53.3 53.3 52.1
Comorbid conditions 6.7 8.2 5.7 5.8 6.7 8.3 11.9 6.7 4.4 7.9
Disagree with CDAI 2.7 10.2 5.7 11.6 6.7 2.1 11.9 10.0 11.1 8.5
Surgery 2.7 1.0 5.7 7.3 3.6 4.2 2.4 13.3 6.7 6.1
Nonrheumatoid arthritis
pain
0 1.0 0 4.4 1.0 0 0 0 2.2 0.6
Pregnancy 0 1.0 1.4 2.9 1.0 0 0 0 2.2 0.6
Tuberculosis 0 0.0 0 1.5 0.3 0 0 0 2.2 0.6
* Values are percentages. Possible reasons for nonacceleration were a new or worsening comorbid condition, anticipated medication response
time lag (e.g., time for the medication to have the maximal effect was inadequate), physician disagreement with CDAI score (considered the
patient as not having moderate/high disease activity), nonrheumatoid arthritis pain was influencing the disease activity measure, recent or pend-
ing surgical procedure, pregnancy, breastfeeding, or planning to become pregnant, history or new diagnosis of human immunodeficiency virus,
hepatitis B virus, or hepatitis C virus, history of positive tuberculin test or equivalent or had not received treatment for latent tuberculosis, and
patient preference.
† More than 1 reason could be reported.
‡ Number of visits with a CDAI score >10.
§ The 10–12+ month group includes visits that occurred after 12 months.
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(Table 2). Patient preference to not accelerate treat-
ment was reported as the reason for nonacceleration in
approximately one-third of cases. Over time, medication
response lag time was less likely to account for nonaccel-
eration, while patient preference was more likely to be
reported as the reason for nonacceleration. Patient prefer-
ence was the most frequent reason for not accelerating
treatment (52%), followed by medication response time
lag (30%), when only eligible new acceleration visits
were considered.
DISCUSSION
To our knowledge, this is the first study that examines both
the feasibility and efficacy of implementing a treat-to-target
approach to care of patients with RA in typical US clinical
practices using a cluster-randomized approach. Specifi-
cally, we found 47% of visits with a CDAI score >10 were
associated with treatment acceleration. Analysis using an
intent-to-treat approach showed that almost 60% of patients
in either arm achieved LDA at 12 months. There was no dif-
ference between the treatment arms with respect to feasibil-
ity, defined by treatment acceleration in the setting of active
disease, or efficacy. Primary reasons for nonacceleration
were patient preference and a perceived need for additional
time for a medication to fully take effect.
Both the usual care and treat-to-target groups had higher
rates of LDA at trial completion than anticipated based on
historical data from CORRONA and from other treat-to-tar-
get trials (2). Further evaluation of the number of visits
among patients in the usual care group suggests that many
of these patients had treat-to-target–like care. This fact
may not be surprising because to participate in the trial,
sites had to be willing to provide treat-to-target care prior
to the cluster-randomization process. Of note, the partici-
pating usual care providers were aware that outcomes
were being compared between the treat-to-target and usual
care groups. Given the growing awareness of the merits of
treat-to-target care, the physicians at usual care sites may
have had greater awareness of the treat-to-target philoso-
phy as part of routine care compared with physicians par-
ticipating in earlier treat-to-target trials. Thus, these
physicians may be early adopters of a treat-to-target–like
approach to care or may have incorporated this approach
during the study. Analyses are underway to explore these
hypotheses by comparing the treatment patterns of the
usual care and treat-to-target arms over time in the years
before and during the treat-to-target trial.
Our results differ from those of other studies evaluat-
ing treat-to-target therapy due to the nature of our trial,
which was designed as a behavioral intervention targeting
US rheumatologists in typical clinical practice and
their patients with moderate or high disease activity. In
previous clinical trials, patients under treat-to-target
management experienced significantly greater improve-
ment in disease activity and higher rates of remission
compared with patients under usual care (3,5). However,
these previous trials targeted patients with early disease
with mandated treatment protocols.
Fransen et al (2) conducted a multicenter, cluster-
randomized trial to compare treat-to-target care with usual
care in the achievement of LDA in 384 patients from 24
centers in The Netherlands. Similar to our study design,
patients were not excluded based on disease duration or
prior csDMARD use, and treatment acceleration strategy
in both arms was left to physician and patient discretion.
Patients were monitored over 24 weeks for achievement of
LDA (DAS28 ≤3.2) and the frequency of changes in
csDMARD treatment. Although significantly more pa-
tients in the treat-to-target arm achieved LDA at 24
weeks compared with the usual care arm, there was no
significant difference in the mean change in DAS28 over
the 24-week study period between the study arms. Fur-
thermore, while csDMARD changes occurred more fre-
quently in the treat-to-target group than the usual care
group, csDMARD treatment changes were made at only
20% of the visits at which DAS28 measured >3.2 in the
treat-to-target arm.
Our study is the first to perform any US-based treat-to-tar-
get trial, and the first to focus on feasibility of treat-to-target
implementation in routine clinical practice in a contempo-
rary US setting. Although prior European clinical trials
demonstrated the benefits of a treat-to-target approach with
mandated treatment acceleration, the implementation of
this approach in the US is potentially challenging, given
different health care payment systems, practice styles, and
patient-provider interactions. Additionally, we crafted a
nonrigid, simple intervention that, if successful, could be
widely disseminated. Of note, because this was a behav-
ioral intervention trial, we did not intervene if providers
were not following the predefined treat-to-target approach.
While all treat-to-target sites received detailed instruction
prior to study initiation and received study reminders,
physicians were not audited for adherence during the
study; patients had agreed conceptually to the principles of
acceleration prior to enrollment.
One inherent limitation of the intervention design of our
study was the inclusion of study sites based on their willing-
ness to implement a treat-to-target approach, which may
have selected for usual care sites predisposed to provide
treat-to-target care and contributed to the similarity in accel-
eration outcomes between the study arms. Patients in both
arms were seen more frequently and had higher rates of LDA
than typically seen in clinical practice (2,6). Lastly, we did
not address patient- or systems-related barriers to a treat-to-
target approach, as our goal was to develop a simple inter-
vention that could be disseminated widely to physicians.
We believe our observations provide unique insights
that enhance the understanding of the challenges to pro-
viding treat-to-target care using clinical disease activity
level as the cutoff metric. Both patient and physician
preference and suspected time lags in medication effec-
tiveness were frequently reported as reasons for nonaccel-
eration. Patient reluctance to accelerate therapy suggests
that practitioners should provide patient-centric tools and
the rationale for acceleration in patients who may feel the
risk of unknown side effects of a new therapy outweighs
the potential benefits of modest improvement in disease
activity (16,17). The psychological dynamic of avoiding a
potential loss, which carries more emotional weight than a
possible gain, has been well documented in decision the-
ory (17). These insights into human behavior are likely
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relevant when rheumatologists try to convince a patient
with low or moderate disease to accelerate to a new treat-
ment and the patient resists due to fear of new side effects
(18,19). Approaches to work within the innate human
propensity to avoid a loss (i.e., a new toxicity) are needed
before widespread patient acceptance of treatment acceler-
ation can be implemented in patients with moderate dis-
ease. These challenges may be more compelling in the US,
where ubiquitous direct-to-consumer advertising is replete
with a mandated litany of potential toxicities, which may
influence patient decision-making.
While treat-to-target management may be more effective
than usual care under optimal conditions, circumstances
in routine clinical practice are rarely optimal. Specifi-
cally, the results of this trial demonstrate the difficulty of
convincing patients of the virtues of treat-to-target care.
Based on the similar frequency of acceleration and treat-
ment outcomes observed in the 2 treatment arms, one
wonders whether benchmarking and motivating providers
is sufficient to achieve a treat-to-target approach to care.
Potentially greater transparency of physician practice per-
formance may result in superior RA disease outcomes.
We hope that these insights provide a fresh consideration
of real-world challenges associated with treat-to-target
implementation in US patients with longstanding dis-
ease. These newly described insights provide a founda-
tion for future investigations by identifying behavioral
impediments to a treat-to-target approach in typical clini-
cal practice in the US.
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